Stockscreener 앱 받기
97.55
6.17%
5.67
시간 외 거래:
97.55
전일 마감가:
$91.88
열려 있는:
$91
하루 거래량:
936.97K
Relative Volume:
1.51
시가총액:
$6.11B
수익:
$362.80M
순이익/손실:
$-205.49M
주가수익비율:
-10.61
EPS:
-9.19
순현금흐름:
$-347.59M
1주 성능:
+16.97%
1개월 성능:
+10.09%
6개월 성능:
-8.99%
1년 성능:
+63.21%
1일 변동 폭
$91.00
$97.67
1주일 범위
$87.28
$97.67
52주 변동 폭
$56.74
$121.90
Blueprint Medicines Corp Stock (BPMC) Company Profile
명칭
Blueprint Medicines Corp
전화
617-374-7580
주소
45 SIDNEY STREET, CAMBRIDGE, MA
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-10-27 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-08-21 | 재확인 | Needham | Buy |
| 2023-07-31 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-06-05 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2023-01-03 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-11-02 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-09-14 | 개시 | Berenberg | Buy |
| 2022-07-08 | 개시 | Oppenheimer | Outperform |
| 2022-06-27 | 개시 | Wells Fargo | Underweight |
| 2022-06-10 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-06-01 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-03-01 | 개시 | Citigroup | Neutral |
| 2022-02-17 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-01-25 | 업그레이드 | Stifel | Hold → Buy |
| 2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-09-30 | 재개 | Stifel | Hold |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-03-31 | 개시 | Credit Suisse | Neutral |
| 2020-12-03 | 개시 | Stifel | Hold |
| 2020-11-02 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-02 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-10-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-15 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-05 | 개시 | Barclays | Equal Weight |
| 2020-03-17 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2019-11-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-10-22 | 개시 | JMP Securities | Mkt Outperform |
| 2019-10-03 | 개시 | H.C. Wainwright | Buy |
| 2019-09-12 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-08-29 | 개시 | Piper Jaffray | Neutral |
| 2019-08-15 | 재개 | Raymond James | Mkt Perform |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2019-05-23 | 재개 | Goldman | Buy |
| 2019-04-03 | 개시 | Morgan Stanley | Overweight |
| 2018-09-25 | 개시 | Leerink Partners | Outperform |
| 2017-12-11 | 재확인 | Goldman | Buy |
모두보기
Blueprint Medicines Corp 주식(BPMC)의 최신 뉴스
Systemic Mastocytosis Treatment Market to Grow by USD 157.1 Million from 2024-2028, Driven by Aging Population and AI-Redefined Market LandscapeTechnavio - The Malaysian Reserve
Blueprint Medicines (NASDAQ:BPMC) Price Target Lowered to $151.00 at Wells Fargo & Company - Defense World
Emerald Advisers LLC Has $34.77 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report - Yahoo Finance
Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Q4 EPS Estimates for Blueprint Medicines Boosted by Wedbush - MarketBeat
Earnings call: Blueprint Medicines sees revenue soar with AYVAKIT sales - Investing.com
Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2024 Earnings Call Transcript - Insider Monkey
Blueprint Medicines stock target upgraded, buy rating on Ayvakit sales - Investing.com
Blueprint Medicines (NASDAQ:BPMC) Receives "Buy" Rating from HC Wainwright - MarketBeat
Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and Raised Guidance - GuruFocus.com
Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and ... - Yahoo Finance
Blueprint Medicines Reports Strong Q3 2024 Results - TipRanks
Blueprint Medicines shares buoyed by Ayvakit sales beat - Investing.com
Blueprint Medicines (NASDAQ:BPMC) Shares Gap UpHere's Why - MarketBeat
Blueprint Medicines Corp earnings beat by $0.07, revenue topped estimates - Investing.com
Needham & Company LLC Reaffirms "Buy" Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Blueprint Medicines: Q3 Earnings Snapshot - Marketscreener.com
Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - Yahoo Finance
When Can We Expect A Profit From Blueprint Medicines Corporation (NASDAQ:BPMC)? - Simply Wall St
Assenagon Asset Management S.A. Lowers Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Corporation (NASDAQ:BPMC): Are Analysts Optimistic? - Yahoo Finance
UBS Group Initiates Coverage on Blueprint Medicines (NASDAQ:BPMC) - Defense World
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Barchart
Analyst Ratings For Blueprint Medicines - Benzinga
Blueprint Medicines (NASDAQ:BPMC) Receives New Coverage from Analysts at UBS Group - MarketBeat
Blueprint Medicines' SWOT analysis: stock outlook amid strong Ayvakit sales - Investing.com
Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Blueprint Medicines (BPMC) Scheduled to Post Earnings on Wednesday - MarketBeat
SG Americas Securities LLC Has $233,000 Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (BPMC) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 - Financial Times
Wall Street Analysts Predict a 41.4% Upside in Blueprint Medicines (BPMC): Here's What You Should Know - Yahoo Finance
Blueprint Medicines Corp [NASDAQ: BPMC] Sees Decrease in Stock Value - Knox Daily
Activin Receptor Type 1 Market Review: All Eyes on 2024 Outlook - IndiaPolitics.com
The Blueprint Medicines Corp (BPMC) had a good session last reading, didn’t it? - US Post News
Brokers Issue Forecasts for Blueprint Medicines Co.'s Q2 2026 Earnings (NASDAQ:BPMC) - MarketBeat
Dimensional Fund Advisors LP Sells 16,619 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Corp [BPMC] Stock sold by Insider Namouni Fouad for $0.32 million - Knox Daily
Holdings of Blueprint Medicines Corp (BPMC) are aligned with the stars - SETE News
Clearbridge Investments LLC Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines executive sells over $324k in stock By Investing.com - Investing.com Australia
Blueprint Medicines executive sells over $324k in stock - Investing.com India
Blueprint Medicines Co. (NASDAQ:BPMC) Insider Fouad Namouni Sells 3,633 Shares - Defense World
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Dana Investment Advisors Inc. - Defense World
Blueprint Medicines Corp [BPMC] Records 200-Day SMA of $94.83 - Knox Daily
Is Blueprint Medicines Corp (BPMC) a good investment opportunity? - US Post News
AQR Capital Management LLC Raises Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Investors in cash trouble should check out Blueprint Medicines Corp (BPMC) - SETE News
Bank of Montreal Can Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Corp (BPMC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):